Digital tools for recording data can transform patient care from a series of episodic snapshots into a continuum, allowing health care providers to deliver the treatments needed faster. Naturally, these tools could be very valuable to pharmaceutical companies – both in pre-market research and post-market surveillance – and many of the biggest players in the sector have either been acquiring or collaborating with digital-only companies to augment their own product portfolios.
One such example of a collaboration between a big pharma company and a medtech is that of AstraZeneca PLC...